Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy

References

• Cazzola M, Malcovati L. Myelodysplastic syndromes–coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536–538.
   PubMed Web of Science ®Google Scholar
• Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res. 2015;39(1):6–17.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Attar E, Bennett JM, et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013;11(7):838–874.
   PubMed Web of Science ®Google Scholar
• De Roos AJ, Deeg HJ, Onstad L, et al. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol. 2010.
   PubMedGoogle Scholar
• Cogle CR, Iannacone MR, Yu D, et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res. 2014;38(1):71–75.
   PubMed Web of Science ®Google Scholar
• McQuilten ZK, Wood EM, Polizzotto MN, et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. Cancer. 2014;120(11):1686–1694.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847–2852.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121–7125.
   PubMed Web of Science ®Google Scholar
• Buckstein R, Jang K, Friedlich J, et al. Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows. Leuk Res. 2009;33(10):1313–1318.
   PubMed Web of Science ®Google Scholar
• Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw. 2011;9(1):57–63.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52–57.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Stone RM. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):389–406.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Garcia-Manero G, Strati P, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015;121(6):876–882.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830–3834.
   PubMed Web of Science ®Google Scholar
• Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–3327.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol. 2011;38:682–692.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49(4):690–695.
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines: Myelodysplastic Syndromes. NCCN Clinical Practice uildines in Oncology. 2013. Version 2. 2014.
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Pan F, Peng S, Fleurence R, et al. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Clin Ther. 2010;32(14):2444–2456.
   PubMed Web of Science ®Google Scholar
• Dacogen (decitabine) [Prescribing Information]. Woodcliff Lake, NJ; Eisai, Inc: 2010.
   Google Scholar
• CMS (Center for Medicare & Medicaid Services). Inpatient PPS PC Pricer Fiscal Year 2014 [Internet]. [cited 2014 Jul 21]. Available from: www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PCPricer/inpatient.html
   Google Scholar
• Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013;48(2):294–300.
   PubMed Web of Science ®Google Scholar
• Lang K, Earle CC, Foster T, et al. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging. 2005;22(11): 943–955.
   PubMed Web of Science ®Google Scholar
• Gidwani R, Khan ZM, Fenaux P, et al. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. J Med Econ. 2012;15(1):145–154.
   Google Scholar
• Goss TF, Szende A, Schaefer C, et al. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Contr. 2006(Suppl 13):17–25.
   Google Scholar
• Bureau of labor statistics, CPI Inflation calculator [Internet]. [ cited 2015 Sep 1]. www.bls.gov/data/ inflation_calculator.htm
   Google Scholar
• PriceRx Wolters Kluwer 2014 [ Internet]. [cited 2014 Jun 26]. Available from: https://pricerx.medispan.com/
   Google Scholar
• Levy AR, Zou D, Risebrough N, et al. Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes. Curr Oncol. 2014;21(1):e29–40.
   PubMed Web of Science ®Google Scholar
• PHAR 2014. Data on File 2014. “Claims Analysis to Quantify the Burden of Illness in Patients with Myelodysplastic Syndromes Eligible for 2nd-Line Therapy”. Conducted by PHAR., LLC in collaboration with Onconova, Inc.
   Google Scholar
• Kurtin SE, Chang E, Bentley TGK. Quality of Life Burden Among Patients with Myelodysplastic Syndrome: Analysis of Survey Data. Blood. 2014;124(21):1303
   Google Scholar
• Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw. 2008;6(9):942–953.
   PubMedGoogle Scholar
• Wang R, Gross C, Frick K, et al. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res. 2012;36(11):1370–1375.
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630–641.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9): 796–797.
   PubMed Web of Science ®Google Scholar
• Wang R, Gross CP, Maggiore RJ, et al. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leuk Res. 2011;35(7):904–908.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–803.
   PubMed Web of Science ®Google Scholar
• Demakos EP, Silverman LR, Lawrence ME, et al. Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents. Poster session presented at 56th ASH Annual Meeting and Exposition.; 2014 Dec 6–9; San Francisco, CA.
   Google Scholar
• Harel S, Cherait A, Berthon C, et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leuk Res. 2015; 39(5):501–504.
   PubMed Web of Science ®Google Scholar
• Apuri S, Lancet JE, Al Ali N, et al. Evidence for selective benefit of sequential treatment with azanucleosides in patients with myelodysplastic syndromes (MDS) [abstract]. ASH Ann Meet Abstracts. 2012. 120:4937.
   Google Scholar
• Prebet T, Charbonnier A, Gelsi-Boyer V, et al. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leuk Lymphoma. 2013;54:1538–1540.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Huang X, Kantarjian H, et al. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010;51:73–78.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010;28:2253–2258.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012;120:4945–4951.
   PubMed Web of Science ®Google Scholar
• Bayraktar UD, Domingo GC, Schmit J, Pereira D. Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2011;52:913–915.
   PubMed Web of Science ®Google Scholar
• Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma. 2008;49:2141–2147.
   PubMed Web of Science ®Google Scholar
• Prebet T, Gore S, Sun Z, et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905 [abstract]. ASH Annual Meeting Abstracts. 2010;116:601.
   Google Scholar
• Cogle CR, Imanirad I, Wiggins LE, et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol. 2010;8(1):40–46.
   PubMedGoogle Scholar
• Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45:255–260.
   PubMed Web of Science ®Google Scholar
• Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol. 2012;30:4533–4540.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18:1211–1218.
   PubMed Web of Science ®Google Scholar
• Physicians’ Fee & Coding Guide. 2014. In Gauge Healthcare Solutions; Atlanta, GA: 2013.
   Google Scholar
• Physicians’ Fee & Coding Guide 2014. InGauge Healthcare Solutions; Atlanta, GA: 2013
   Google Scholar